Company news
Nuvalent, Inc. news in 2026
Nuvalent, Inc.'s news releases, calls and decks from 2026, newest first.
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
June 10, 2026
Nuvalent: GSK enters agreement to acquire Nuvalent, Inc.
June 9, 2026
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
May 26, 2026
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
May 7, 2026
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
April 20, 2026
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
April 17, 2026
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
April 6, 2026
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
March 16, 2026
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
January 12, 2026